Bactiguard Holding

Capital/Financing Update • Dec 13, 2016

Press release Stockholm, 13 December, 2016

Bond loan repaid

Bactiguard outstanding bond loan was repaid in full on 12 December. The refinancing solution consists of loans totaling SEK 150 million.

The bond loan Bactiguard issued in December 2011, with an initial nominal value of SEK 450 million, an annual interest rate of 11% and a duration of 5 years, matured on 12 December.

The outstanding nominal value of SEK 138 million and accrued interest have now been paid in full. The refinancing solution consists, as previously communicated, of two loan commitments which now have been utilized in the form of a bank loan of SEK 100 million maturing 31 December, 2017 and a loan from the company's main shareholders of SEK 50 million maturing 30 June 2018. The loans carry a base interest rate of STIBOR 90, but not less than 0%, and a margin of 3.5%.

Bactiguard's interest expenses will be substantially reduced by this refinancing. At the same time, the company is working on securing a long-term financing solution at a competitive rate.

For further information, please contact:

Fredrik Järrsten, CFO, mobile: +46 72 550 00 89

This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CET on 13 December, 2016.

About Bactiguard

Bactiguard is a Swedish medtech company with a mission of preventing healthcare associated infections, reducing the use of antibiotics and saving lives by developing and supplying infection prevention solutions for the healthcare industry. The company's patented coating prevents healthcare associated infections by reducing bacterial adhesion and growth on medical devices. Bactiguardcoated urinary catheters are market leading in the US and Japan, and in recent years the company has developed its own product portfolio of catheters for the urinary and respiratory tract and the blood stream. Bactiguard is currently in a strong expansion phase, focused on new markets in the Europe, Middle East, Asia, South America and Southern Africa. The company has market presence in some 50 countries and has about 60 employees. Its headquarters is located in Stockholm and production facilities in Sweden and Malaysia. Bactiguard is listed on Nasdaq Stockholm. Read more about Bactiguard at www.bactiguard.com.